Enter The Fair, Transnational Pharmaceutical Companies Frequent Show New Products Acceleration Mode Innovation And Localization

As the second largest pharmaceutical market in the world, China has become the engine of growth for most multinational pharmaceutical companies in recent years. As in the past, most companies mentioned the high growth in China's market in the third quarter earnings reports recently released. For example, Novartis said its emerging market sales increased by 10%, mainly driven by China's two digit growth.

The rapid growth of the Chinese market has made it impossible for multinational pharmaceutical companies to "refuse". From the second coming fair, we can see that the enterprises are becoming more positive.

According to Wu Jun, director of the medical exhibition area of the second fair, the 7.1 and 7.2 museums of medical devices and health care are the first "full Pavilion" exhibition area of this year's Expo. Not only are there many new enterprises to enter, but also enterprises have booked the next third and fourth sessions of the Expo. In January 31st this year, the 7.1 pavilions completed the investment promotion, and then developed half a pavilion in the 7.2 Pavilion. After the exhibition was completed in March, the exhibition area increased to 45 thousand square meters.

For instance, AstraZeneca and the first exhibition of Mercedes in this year are as high as 800 square meters. They are the two largest enterprises in the medical equipment and health care exhibition area.

As a highly related industry with performance and policy, health care has been affected by the policy of "4+7" purchasing, landing, expanding, national medical insurance cataloging, negotiation and so on. Multinational pharmaceutical companies have expressed their determination at the fair. In addition to frequent new product frequency contracts, they are constantly innovating more local business models.

Innovation and localization

In November 5th, GE medical showed the world's first artificial intelligence CT system APEX CT, which was awarded the US FDA certification and authentication based on the deep learning and reconstruction algorithm. At the same time, it signed a memorandum of scientific research cooperation with Ruijin hospital. It will carry out research courses on major diseases on APEX CT.

The 3 new global products, including a fully automated microbial identification drug sensitivity analyzer, are being presented. The aim is to identify new drug resistant phenotypes and monitor the trend of antibiotic resistance, and to provide the latest antibiotics selection through cooperation with pharmaceutical companies.

Benefiting from accelerated review and approval in recent years, pharmaceutical companies have brought more new drugs listed in China.

GlaxoSmithKline (GSK) exhibits Bailey's specific monoclonal antibody against the treatment of systemic lupus erythematosus (SLE). Since 1996, the B lymphocyte stimulator was first approved by FDA in 2011, and the development and listing of Bailey's monoclonal antibody took 15 years. In mid July this year, Bailey's monoclonal antibody was approved in China and the first prescription was issued in September 20th.

In November 6th, Roche anti flu innovative medicine Xofluza was first unveiled in front of the public. Compared with the current anti influenza drugs, Xofluza can shorten the time of virus detoxification by about 2 days. At the same time, Roche signed a strategic cooperation agreement with the first district of Le Cheng International Medical Tourism in Hainan Province, and took the lead in bringing the drug into the Hainan leading area through the Hainan free trade zone's "first try" policy. At present, Xofluza has been approved in 9 countries and regions around the world, and the China drug administration has also approved Xofluza to conduct clinical trials in China.

Gu Gang, director of the administration of the first district of Hainan Boao Le Cheng international medical tourism, said, "the pioneer area has made many explorations in the innovation of medical mode. Through the signing of the framework agreement with Roche pharmaceutical, we hope to introduce more innovative drugs into the leading area, so that more Chinese patients can enjoy the world's most advanced treatment without going abroad. We also hope that more innovative drugs from other companies will enter the leading area.

Benefit from negotiating price cuts into the national health insurance directory, Novo nordk's star hypoglycemic drug, rrrp, increased sales by 73% in 2018, with revenue of 521 million dkrona, or about 534 million yuan. In November 6th, Novo Nord first exhibited the products of de Valley double Neutrul Insulin Injection and the new member of the national health insurance directory, Tak Gu Neutrul Insulin Injection, in 2019.

Among them, de Gu Dong Dong Shuang Neutrul Insulin Injection was included in the national priority examination and approval catalogue of innovative drugs in September 2018. In May this year, the product was approved by the State Drug Administration to be listed for the treatment of adult type 2 diabetes.

Zhou Xiaping, senior vice president and chief China officer of Novo Nord, told the twenty-first Century economic report that "novo Nord China has made great progress in the past year, benefiting from the continuous optimization of China's business environment and the development opportunities brought by China's medical reform."

Innovative business models

In addition to innovative products, more multinational pharmaceutical companies will enter the fair as an innovative platform to explore the possibility of expanding the market.

In recent years, AstraZeneca has made a number of contracts at the fair, which has been eye-catching in the Chinese market: AstraZeneca and CICC announced the joint establishment of the global medical and health industry fund. It is the first and largest medical and health industry fund raised by AstraZeneca in the world. The target of financing is expected to reach US $1 billion in the future. It will be located in Wuxi, Jiangsu, China, focusing on the whole industrial chain, including the development, production, operation and commercialization of new drugs worldwide.

As a typical representative of policy benefits, AstraZeneca's three quarterly report shows that Q3 sales in the Chinese market were $1 billion 283 million, and sales in the first nine months increased by 30% to 3 billion 691 million US dollars in 2019.

"We grew by 28% in the first quarter of this year, 44% in the two quarter and 45% in the three quarter. It is also one of the top ranked multinational pharmaceutical companies in China." Wang Lei, global executive vice president of AstraZeneca, international business and President of China, told the twenty-first Century economic report that "introduction, innovation, cooperation and expansion are most important to us." Decentralization and localization make AstraZeneca more like a domestic company in China, but also sell international medicines. At the fair, we not only display products, but also show different kinds of cooperation, treatment, business and so on.

In November 6th, Pfizer came to the fair with innovative products such as cancer, anti infection and vaccine. At the same time, Pfizer signed a cooperation agreement with Jinyu medicine, Microsoft and China rare disease alliance, an inter disciplinary and cross industry innovative cooperation mode.

The platform of the fair has also promoted similar multi-party cooperation projects. In November 6th, Novartis ophthalmologists and ophthalmologists, medical institutions and trade associations jointly launched the "eye health alliance". They will focus on six blindness diseases, including cataract, glaucoma, diabetic retinopathy, corneal diseases, age-related macular degeneration and high myopia.

In November 7th, Senauer Faye Basudeb released the digital innovation program of vaccines, and reached an intentional strategic cooperation with the Chinese Preventive Medicine Society, Ali health and Shensu group of the Chinese Academy of Sciences.

Mercedes is also one of the biggest beneficiaries of accelerated medical review and approval reform in recent years. The "rocket speed" of HPV vaccine has been approved as a typical industry.

In the third quarter of 2019, Mercedes international sales accounted for 54% of the total sales of the quarter. The Chinese market was the best performing market in its international market. Q3's revenue was $898 million, up 84% from the same period last year, mainly driven by the quadruple and nine price of HPV vaccine and tumor drugs.

Benefit from the vaccine, we also review the vaccine: in November 7th, Mercedes held the 30th anniversary special activity of China's hepatitis B vaccine technology transfer at the fair. In 1989, Mercedes reached an agreement with the Chinese government to transfer the world's most advanced genetic engineering hepatitis B vaccine production technology to China. Luo Wanli said, "with the help of the Expo, this platform will celebrate the great achievements China has made in the field of hepatitis B prevention. At the same time, it also hopes to discuss with industrial partners how to continuously improve China's public health and support the Chinese government's efforts to achieve" healthy China 2030 ".